Erythropoietin (EPO) acts on erythroblasts in the bone marrow (BM) to stimulate the formation of red blood cells. In this study, we wanted to determine whether BM-derived mesenchymal stromal cells (MSCs) can be used as cellular vehicles to deliver EPO in mice without the use of viral vectors. After isolation and characterization of murine MSCs (mMSCs), different transient transfection procedures were compared for their efficacy of gene transfer of the pEGFP-N2 plasmid. Nucleofection outperformed magnetofection and lipofection. Stably transfected mMSCs were generated by selection with G418-disulfate and single-cellcolony-forming unit (sc-CFU) assays without changes in their proliferation capacity and osteogenic/adipogenic differentiation potential. Next, murine EPO was stably introduced into mMSCs by nucleofection of a plasmid encoding the epo and egfp genes. Intraperitoneal transplantation of EPO-expressing mMSCs increased serum EPO levels, hematocrit and hemoglobin of C57BL/6 mice within 1 week. The hematocrit remained elevated for 5 weeks, but production of antibodies against both transgenes was detected in the hosts and serum EPO levels normalized. Our results suggest that nonviral gene delivery into MSCs can be used to enhance the known beneficial effects MSCs by additional production of therapeutic factors like EPO in vivo.
INTRODUCTION
Before the discovery of erythropoietin (EPO), patients with anemia required repeated blood transfusions, which carried the risk of infections and iron overload. Cloning of the EPO gene in 1985 1 paved the way for the production of recombinant EPO, which has revolutionized the treatment of anemia. Endogenous human EPO is a 165 amino-acid glycoprotein hormone, which is primarily produced by interstitial fibroblasts in the kidneys in response to hypoxemia. EPO binds to a homodimeric receptor on hematopoietic progenitors and erythroblasts to stimulate the formation of erythrocytes. Interestingly, EPO is also synthesized in the liver, uterus and even in the brain, suggesting diverse biological functions. In fact, EPO has important cyto-and tissue-protective effects, and contributes to neuroprotection and wound healing responses. 2, 3 Numerous in vivo gene therapeutic approaches for the delivery of EPO have been made in rodents and non-human primates, including the use of adenovirus, adeno-associated virus, retroviral and lentiviral vectors. [4] [5] [6] [7] Nonviral epo gene transfer has been achieved with intramuscular injection of a plasmid DNA vector, administration of naked DNA or electroporation. 8 In order to obtain sustained delivery of therapeutic plasma levels of EPO, cell-based gene therapy has become an attractive alternative, which combines ex vivo genetic engineering with cell therapy. Among the many gene-modified cell types, mesenchymal stromal cells (MSCs) are particularly promising because of their versatile functions. This includes their plasticity with differentiation potential into various types of mesodermal tissues, as well as their excellent targeting capabilities. [9] [10] [11] Besides the idea that MSCs naturally function to replace cells, they also appear to provide trophic support and exert immunomodulatory effects. 12 Importantly, MSCs express very low levels of major histocompatibility complex (MHC) molecules. Moreover, allogeneic MSCs do not elicit a proliferative response from lymphocytes, suggesting that they are of inherently low immunogenicity. 13 MSCs can inhibit the production of effector T helper 1 cytokines, induce the generation of regulatory T cells and promote the generation of tolerogenic antigen-presenting dendritic cells. 13 Therefore, MSCs have become one of the most popular cell types for in vivo therapeutic protein production. 11 A few recent studies have successfully used viral transfer of the epo gene into non-human primate, rodent and human MSCs for cell-based gene therapy. [14] [15] [16] [17] Here, we wanted to establish nonviral techniques for MSC-based delivery of EPO. This study is the first to examine nucleofection of MSCs for epo gene delivery in vivo. We found that nucleofection provides stable transfection of MSCs and production of biologically active EPO by MSCs both in vitro and in vivo.
RESULTS

Characterization of mMSCs
Assessment of the proliferation properties of murine MSCs (mMSCs) was carried out by a growth kinetic analysis. mMSCs showed more than eight cell doublings during a culture period of 7 days in vitro (div) (Figure 1a ). Plasticity of mMSCs was confirmed by differentiation into osteoblasts (Figures 1b and c) , adipocytes ( Figure 1d ) and chondrocytes ( Figure 1e ). Fluorescence-activated cell sorting (FACS) analysis of mMSCs revealed expression of the stem cell marker Sca1, CD29 (b 1 integrin), CD44 and CD80 ( Figure 2 ). In addition, a small sub-population of mMSCs (o2%) expressed CD40. In contrast, mMSCs were negative for hematopoietic markers like CD11b, CD34, CD45, CD45R/B220, Ter119/Erythroid cells, Ly6G/Ly6C and CD3e, endothelial markers like CD31 (PECAM-1), Flk1 (VEGF-R2) or VCAM1 (CD106), stem cell markers like CD90.1, CD90.2 and CD117 (c-kit), and CD86 or MHC class II (Figure 2 ).
Transient transfection of mMSCs with the pEGFP-N2 plasmid
To date, no protocol for nucleofection of bone marrow (BM)-derived mMSCs exists. We therefore tested different nucleofection buffers and programs of the Amaxa nucleofector device (Lonza, Verviers, Belgium) to optimize transfection conditions. A comparison of programs A-23, A-24, A-30, C-17, T-05, T-16, T-20, T-23, T-27,  U- Nonviral gene transfer into murine MSCs F Scheibe et al nucleofection of 1Â10 6 mMSCs with 5 mg DNA in nucleofection buffer from the Nucleofector Kit for rat neurons (Lonza). After transfection, a recovery of 37±1% of mMSCs with a viability of 94 ± 1% was achieved. Thus, B22% of the original cell population both survived and was modified by nucleofection.
Magnetofection of mMSCs resulted in transfection rates of 30±2% (Figure 3a) , whereas highest efficiencies of nonviral gene transfer into mMSCs with a cationic lipid were obtained by transfection with Lipofectamin (Invitrogen, Darmstadt, Germany; 23±2%; Figure 3a ). Other cationic lipids like Polyfect (Qiagen, Düsseldorf, Germany) or Metafectene (Biontex, Munich, Germany) were far less efficient for mMSC transfection (data not shown).
Initial expression of green fluorescent protein (GFP) in mMSCs was already visible at 6-8 h post transfection. The percentage of GFPexpressing mMSCs was determined by FACS at 2, 4, 7, 14 and 21 days post transfection. After 14 days, o10% of mMSCs in culture expressed GFP (Figure 3a ).
Stable transfection of mMSCs with the pEGFP-N2 plasmid
Stably transfected mMSCs were obtained by all three transfection methods after selection with 400 mg ml -1 geneticin for 14 div and using single-cell-colony-forming unit (sc-CFU) assays. For this purpose, a single GFP-expressing cell was sorted into each well of a 96-well plate, giving rise to one or more new colonies that were further expanded and analyzed by FACS. All transfection methods yielded mMSC clones, which stably expressed GFP (Figures 3b and c) . After selection with the antibiotic, B1% of the seeded cells stably integrated the transgene (nucleofection: 0.7%, magnetofection: 1%, lipofection: 1.4%). Quantification of GFP expression after stable gene transfer revealed that mMSC clones obtained by nucleofection, magnetofection and lipofection expressed GFP in up to 96%, 98% and 92% of cells, respectively (Figures 3b and c) . Re-analysis of GFP expression 4 passages later confirmed long-term GFP expression (Figure 3d) .
After stable transfection, GFP-expressing mMSCs (Figures 4a-c) were continued to be cultured under selection pressure with geneticin, and they retained their differentiation potential into osteoblasts (Figures 4d-f ) and adipocytes (Figures 4g-i) . As Alizarin Red S staining resulted in fading of the GFP signal, osteogenic differentiation cultures were immunostained against GFP before histological Alizarin Red S staining was performed (Figures 4e and f) .
Moreover, the proliferation capacity of stably transfected mMSCs was not different from untransfected controls (data not shown). GFP clones were usually expanded for 30-32 cell doublings during a cultivation period of B4 weeks (4 passages).
Expression of EPO after nucleofection of mMSCs with the pEPO-IRES2-EGFP plasmid After nucleofection with pEPO-IRES2-EGFP, 26±5% of mMSCs transiently expressed GFP at 48 h (Figure 5a ). After 7 days, GFP expression was reduced to 7 ± 2% of mMSCs, and was virtually abolished after 14 days. Similarly, mMSCs transfected with pEPO-IRES2-EGFP secreted EPO in concentrations of 64 ± 21 ng ml -1 EPO after 48 h, 92 ± 19 ng ml -1 EPO after 4 days and 58 ± 14 ng ml -1 EPO after 7 days, when no medium change was performed. If medium was replaced after 2 and 4 days, supernatants only contained 20 ± 6 ng ml -1 after 4 days and 7 ± 3 ng ml -1 after 7 days ( Figure 5b) . As a control, mMSCs were nucleofected with pEGFP-N2 and no expression of EPO was observed (Figure 5b ).
Stably EPO-expressing mMSCs were generated by nucleofection as described above, resulting in clones with variable transgene expression. Up to 80% of mMSCs expressed GFP in stably transfected mMSCs, but GFP expression was reduced by half after four passages (Figures 5c and d) , suggesting weaker expression/silencing of the gene downstream of the internal ribosomal entry site. In contrast, expression levels of EPO within a given clone were maintained over four passages ( Figure 5e ). As a control, mMSCs were stably transfected with pEGFP-N2 and no expression of EPO was observed ( Figure 5e ). As for the transient transfection, stable gene transfer of pEPO-IRES2-EGFP into mMSCs neither affected their proliferation capacity nor their differentiation potential into the osteogenic and adipogenic lineages (data not shown).
A colony-forming unit-erythroid (CFU-E) assay was used to confirm that mMSCs produced biologically active EPO. Supernatant from mMSC cultures transfected with pEPO-IRES2-EGFP, which contained 15 ng ml -1 EPO by enzyme-linked immunosorbent assay (ELISA), was compared with 1.5 U ml -1 commercially available recombinant human EPO for erythropoietic activity. Control medium without EPO served as negative control. The mMSC-derived EPO stimulated erythropoiesis to the same degree as recombinant human EPO (Figure 5f ).
To confirm the presence of the transgenes in mMSCs stably transfected with pEPO-IRES2-EGFP or pEGFP-N2, DNA was extracted and analyzed by PCR. Untransfected mMSCs served as negative control. PCR analysis confirmed the presence of pEPO-IRES2-EGFP and pEGFP-N2 sequences in stably transfected mMSCs after passage 14 ( Figure 5g ). 
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Hematopoietic activity of EPO-expressing mMSCs in vivo
To test whether stably transfected transgenes can be expressed in mMSCs in vivo and are able to modify biological parameters, we transplanted 2Â10 7 mMSCs after stable transfection with pEPO-IRES2-EGFP on day 0 and 1Â10 7 EPO-producing mMSCs on days 2 and 3, respectively, by intraperitoneal (i.p.) injection into C57BL/6 mice. Control animals received either mMSCs stably transfected with pEGFP-N2 or PBS at the same concentrations and time points via i.p. injection.
At 1 week after transplantation, peripheral blood samples were analyzed for hematocrit, hemoglobin and serum EPO levels (Figures 6a-c). Transplantation of EPO-expressing mMSCs increased the hematocrit to 61 ± 2%. In comparison, animals that received GFPexpressing mMSCs or phosphate buffered saline (PBS) had hematocrit levels of 47±2% (Figure 6a ). In line with these data, hemoglobin levels increased from 11.6 ± 0.3 g dl -1 in the GFP-expressing mMSC group and 11.6 ± 0.8 g dl -1 in the PBS group to 14.0 ± 0.3 g dl -1 in animals that received EPO-expressing mMSCs (Figure 6b ). Serum EPO levels reached values of 238.6±65.2 pg ml -1 in the EPOexpressing mMSC group, whereas the GFP-expressing mMSC group showed only values of 84.6±42.8 pg ml -1 and the PBS group 103.4±27.2 pg ml -1 ( Figure 6c ).
In order to assess the time course of hematocrit, hemoglobin and serum EPO changes, peripheral blood samples were collected on a weekly basis. The hematocrit remained significantly increased at 5 weeks after transplantation in the EPO-expressing mMSC group (52 ± 3%) compared with the GFP-expressing mMSC group (48 ± 2%) and the PBS group (48 ± 2%; Figure 6a ). The hematocrit normalized after 6 weeks. Elevated levels of hemoglobin (14.1 ± 0.4 g dl -1 ) and serum EPO (143.3 ± 23.6 pg ml -1 ) persisted for 3 weeks after transplantation in the EPO-expressing mMSC group (Figures 6b and c) .
We next analyzed serum samples for antibody production against the transgenes GFP and EPO. Anti-EPO antibodies were detected in all animals after transplantation of EPO-expressing mMSCs, whereas these antibodies were absent in mice that received GFP-expressing mMSCs or PBS ( Figure 6d ). As EPO-expressing mMSCs had been stably transfected with pEPO-IRES2-EGFP, we also wanted to determine antibody production against GFP in the recipient mice. Indeed, anti-GFP antibodies were detected in the EPOexpressing mMSC group and in the GFP-expressing mMSC group, but not in the PBS group (Figure 6e ). Increased antibody titers against EPO and GFP were detected 2, 3, 4 and 5 weeks after transplantation, and titers remained elevated for several weeks thereafter without reaching statistical significance (Figures 6d and e) . Repetitive injections (days 0, 2 and 3) of cell culture supernatants from EPOexpressing mMSCs and GFP-expressing mMSCs did not lead to transgene-directed antibody production, suggesting that the presence GFP-expressing mMSCs (h) were exposed to adipogenic differentiation medium. They differentiated into adipocytes as shown by Oil Red O staining (g). The overlay of images (g) and (h) is shown in (i); n¼3, scale bars¼100 mm (g-i).
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To address the question of whether anti-EPO antibody production in vivo might result from an aberrant protein structure of the mMSCderived EPO molecules, we performed EPO-immunoprecipitation experiments. Conditioned media from EPO-expressing mMSCs were immunoprecipitated with a commercially available antibody against EPO. Supernatants from GFP-expressing mMSCs served as negative control, and commercially available recombinant murine EPO served as positive control. Western blot analysis of precipitates revealed that recombinant murine EPO and mMSC-derived EPO showed bands of the same molecular weight (Figure 6f ). However, immunoprecipitates from the supernatants of EPO-expressing mMSCs contained a faint second band of higher molecular weight, suggestive of another EPO isoform, which was not present in the immunoprecipitates from GFP-expressing mMSCs (Figure 6f ). This EPO isoform might be responsible for triggering an immune response against mMSC-derived EPO in vivo.
DISCUSSION
MSCs are promising candidates for gene delivery to treat hematological diseases like anemia 18 and neurological diseases like stroke. 19 So far, viral techniques have been predominantly used for therapeutic protein production by MSCs. Our study is the first to examine nonviral nucleofection of MSCs for epo gene delivery in vivo. This has important clinical implications as (1) MSCs have already entered the clinical arena in regenerative medicine because of their tropism and therapeutic potential, (2) gene therapy using viral vectors remains In contrast, secretion of EPO into the medium was maintained between passage 11 and passage 15 mMSCs stably nucleofected with pEPO-IRES2-EGFP (e). Data are expressed as ng EPO per ml culture medium quantified by ELISA on days 1, 2 and 3 after plating (n¼3). Stable nucleofection with pEGFP-N2 served as negative control (CTR). (f) Erythropoietic activity of EPO-expressing mMSCs in vitro. Supernatant from mMSC cultures stably transfected with pEPO-IRES2-EGFP (15 ng ml -1 EPO determined by ELISA) was compared with commercially available recombinant human EPO (1.5 U ml -1 rhEPO) in CFU-E assays. Control medium from BM cultures without EPO served as negative control (CTR). Data are expressed as number of CFU-E per 200 000 BM cells after 48 h (n¼3). (g) DNA was extracted from passage 14 mMSCs stably transfected with pEPO-IRES2-EGFP or pEGFP-N2, and analyzed by PCR for the presence of the transgenes. Untransfected mMSCs and H 2 O served as negative controls. PCR for b-actin served as internal control.
Nonviral gene transfer into murine MSCs F Scheibe et al associated with safety concerns and (3) the formation of neutralizing antibodies impairs epo gene delivery in vivo. Our study provides novel information on the post-translational modification of MSC-derived EPO, which may help to explain undesired immune responses.
We find that nonviral gene delivery methods provide efficient gene transfer into mMSCs in vitro and in vivo. Nucleofection resulted in mMSCs, which secreted sufficient amounts of EPO to increase the hematocrit of mice for at least 1 month. Similar results have been reported for viral experiments, in which MSCs were transduced with an EPO-encoding retrovirus. The i.p. injection of 10 5 -10 7 EPOexpressing MSCs induced a cell dose-dependent increase of hematocrit that reached up to 88% and dropped to baseline after B15 weeks. Plasma EPO levels were also found to be elevated for up to 7 weeks. 16 In comparison, subcutaneous transplantation of 10 7 EPO-engineered MSCs showed hematocrit levels that were increased to 70-80% and returned to normal after 40-50 days. 20, 21 We i.p. transplanted mice with 4Â10 7 mMSCs, which were nucleofected with an EPO-encoding plasmid. Hematocrit increased to 460%, and remained elevated for 41 month. Thus, nonviral gene delivery of EPO by MSCs is not quite as efficient as viral strategies, but could nevertheless be an attractive alternative to viral transduction for short-term gene delivery. In particular, virus-mediated gene therapy is still confronted with a number of safety concerns. Viral fragments inserted into the host genome are often associated with high immunogenicity. 22 Moreover, recombination events are a serious safety risk, and retroviruses preferentially integrate into transcriptionally active regions within the host genome. 22 It is therefore not surprising that nonviral gene delivery methods have recently attracted more attention. For example, gene electrotransfer with EPO to mouse skin was shown to provide therapeutic levels of EPO for 3-8 weeks. 23, 24 A similar efficiency was achieved as with our cell-based approach, which will benefit from the tropism of MSCs and their additional tissue-supportive effects.
Intrabone transplantation 25 of MSCs might be a powerful strategy for targeted delivery of EPO-secreting MSCs in anemia, providing highest concentrations of therapeutic protein in close proximity to hematopoietic cells.
One of the challenges of cell-based gene therapy is the survival of the gene-modified cells in the host environment. MSCs are very well suited for allogeneic transplantation, as they are of comparatively low immunogenicity. 13 However, numerous studies suggest that MSCs do not persist in the recipient organism for prolonged periods of time. 26 We detected GFP-expressing cells in the liver, intestinal tract and lymphoid tissues at 7 days post transplantation, but the results were ambiguous (data not shown). In most settings, the survival of MSCs does not exceed the maximal duration of transgene expression after nonviral gene transfer. At a first glance, this may appear to limit the utility of MSCs for gene delivery, but in some instances the disappearance of the grafted cells after a defined period of time could also be advantageous. For example, in acute disorders like myocardial infarction, 27 short-term delivery of therapeutic factors (for example, EPO), 28 for the purpose of cytoprotection and regeneration might be favorable. Persistence of the grafted cells and/or prolonged transgene expression might even result in adverse effects. Thus, intravenous administration of MSCs after acute myocardial infarction in pigs improved cardiac function, but also resulted in significantly shorter effective refractory periods, ascribing a proarrhythmic potential to MSC transplantation. 29 The discovery of bone formation in the heart after MSC delivery was even more alarming. 30 However, we did not observe any calcifications or tumor formation at the transplantation sites (data not shown).
Besides graft survival, the efficiency of EPO gene therapy can also be limited by the production of anti-EPO antibodies in the host. This phenomenon has been observed in mice after subcutaneous transplantation of 10 7 mMSCs transduced with a murine EPO-encoding Figure 6 Hematopoietic activity of EPO-expressing mMSCs in vivo. Adult C57BL/6 mice were transplanted with 4Â10 7 mMSCs stably transfected with pEPO-IRES2-EGFP (EPO) by i.p. injection; control animals received either mMSCs stably transfected with pEGFP-N2 (GFP) or PBS (n¼3-9 for each group). Hematological analysis of peripheral blood samples was performed weekly for up to 6 weeks after transplantation. After 1 week, animals in the EPO group showed a significant increase in hematocrit (a), hemoglobin (b) and serum EPO levels (c) compared with the GFP and PBS control groups. Hematocrit remained elevated for 5 weeks in the EPO group and normalized thereafter (a). Hemoglobin (b) and serum EPO levels (c) were significantly increased in the EPO group for up to 3 weeks. (d) ELISA for anti-EPO antibodies revealed a significant humoral immune response in mice that received mMSCs stably transfected with pEPO-IRES2-EGFP compared with the GFP and PBS control groups. (e) Anti-GFP antibodies were detected in animals that received mMSCs stably transfected with pEPO-IRES2-EGFP (EPO) or pEGFP-N2 (GFP), but not in PBS-injected animals. (f) Western blot of EPO immunoprecipitation from cell culture supernatants of EPO-expressing mMSCs revealed two EPO isoforms in contrast to recombinant murine EPO (rmEPO) with only a single band. Arrows indicate EPO bands; asterisk indicates antibody heavy chains. *Po0.05, **Po0.001.
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F Scheibe et al retrovirus. 31 After a rapid increase in hematocrit, the values returned to normal within 5 weeks after syngeneic transplantation. Allogeneic MSCs induced the formation of neutralizing anti-EPO antibodies with secondary anemia. 21 Whereas the mechanisms leading to autoimmune responses are still unclear, there was no evidence that the EPO secreted by MSCs was the cause of the immune response. 31 Therefore, we hypothesized that the production of anti-EPO antibodies in the host might be associated with changes induced by the viral transduction of MSCs. However, our results refute this hypothesis, as nucleofected EPO-secreting MSCs also induced the production of antibodies against EPO and the second transgene, GFP, in immunocompetent mice. GFP is a foreign protein to the murine host, which may explain the humoral immune response. In the case of EPO, we found an aberrant immunoprecipitate from the supernatants of EPO-expressing MSCs, which may result from alterations in post-translational protein modifications (for example, glycosylation pattern) of MSC-derived EPO. This may have triggered a breakdown in tolerance involving T-and B-cell immune responses with subsequent autoantibody formation. 32 In fact, formation of antidrug antibodies is a common complication associated with therapeutic proteins. 33 Importantly, repeated injections of MSC supernatants into recipient mice did not result in antibody formation. This may be because of the comparatively low concentrations of foreign protein compared with the transplantation of GFP/EPO-producing MSCs. It should be noted that repeated injections of MSC supernatants (on days 0, 2 and 3) also did not result in significant increases of the hematocrit in vivo.
In this study, we established new techniques of nonviral gene transfer into mMSCs (stable transfection). Nucleofection has been used successfully for transient transfection of human, bovine, rat and porcine MSCs, but has never been tested in BM-derived mMSCs. [34] [35] [36] [37] Magnetically enhanced nucleic acid delivery (magnetofection) has not explored for any type of MSCs to date. We found that nucleofection is a very efficient transfection technique for mMSCs with transfection rates of B60%. This is in line with nucleofection data obtained for human MSCs, where transfection rates ranged from 42 to 88%. 36, 38, 39 Magnetofection yielded transient transfection rates of 30% in mMSCs, whereas lipofection only reached B20%. Earlier reports on lipofection of human and rat MSCs with Lipofectamine described transfection rates of 2% and 20%, respectively. 40, 41 Importantly, none of the transient transfection techniques we employed in mMSCs resulted in impaired cellular functions, such as proliferation and differentiation. Moreover, transgene expression was maintained even after differentiation of gene-modified mMSCs into adipocytes and osteoblasts. In contrast, many stem cells loose transgene expression after differentiation as a result of epigenetic modifications. 42 In conclusion, we find that nucleofection can be used to generate EPO-engineered MSCs, which secrete biologically active EPO in sufficient amounts to stimulate hematopoiesis in vivo. Future strategies aimed at the prevention of graft loss (for example, encapsulation of MSCs, exploitation of tissue tropism) 11, 16, 20 and inhibition of autoimmune responses are likely to extend the duration of action of this nonviral cell-based gene therapy where required.
MATERIALS AND METHODS
Isolation and culture of mMSCs
BM was isolated from tibias and femurs of C57BL/6 mice aged 8-12 weeks (BfR, Berlin, Germany). Each bone was flushed with 5 ml complete cell culture medium (CM) consisting of a-minimal essential medium, 2 mM L-glutamine, 100 U ml -1 penicillin and 100 mg ml -1 streptomycin (Biochrom AG, Berlin, Germany), and 20% fetal calf serum (Lonza) using 23-and 25-gauge needle syringes. The cells were centrifuged for 10 min at 200 g, resuspended and plated at a density of 1Â10 6 cells cm -2 into 25 cm 2 flasks. BM cells were cultured in CM at 37 1C and 5% CO 2 . Cells were incubated for 24 h before they were washed twice with PBS to discard the nonadherent cell population. After 5 days in culture, cells were trypsinized for 2 min at 37 1C and were seeded in a dilution of 1:2. All following passages were plated at a density of 50 cells cm -2 , and medium changes were performed every 3 to 4 days. Passages were performed every 10-14 div up to passage 7, and every 7 div thereafter. Cells were frozen in 1 ml aliquots with a-minimal essential medium, 30% fetal calf serum, 2 mM L-glutamine, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and 5% dimethylsulfoxideDMSO (Sigma, Deisenhofen, Germany), and stored in liquid nitrogen. Frozen vials were quickly thawed at 37 1C and replated into a 145 cm 2 dish. After 24 h, cells were trypsinized and seeded at 50 cells cm -2 for further expansion.
Differentiation assays
To differentiate mMSCs into the adipogenic, osteogenic and chondrogenic lineages, passage 8 cells were induced as described previously. 43, 44 For fat and bone differentiation, mMSCs were plated at a density of 50 cells cm -2 into 58 cm 2 Petri dishes and expanded for 4-6 div in CM before replacement by differentiation medium. Adipogenesis was induced by addition of a-minimal essential medium, 10% fetal calf serum, 2 mM L-glutamine, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin, 5 mg ml -1 insulin (Sigma), 50 mM indomethacin (Sigma), 1 mM dexamethasone (Sigma) and 0.5 mM 3-isobutyl-1-methylxanthine (Sigma) for 21 days. Afterwards, cells were fixed with 10% formalin, and stained with 0.5% Oil Red O (Sigma) for 20 min at room temperature (RT). Osteogenic differentiation medium consisted of a-minimal essential medium, 10% fetal calf serum, 2 mM L-glutamine, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin, 20 mM b-glycerol-phosphate (Sigma), 50 ng ml -1 thyroxine (Sigma), 1 nM dexamethasone and 50 mg ml -1 L-ascorbate -2-phosphate (Sigma). After culture for 21 div, cells were fixed with 10% formalin, and stained with Alizarin Red S (Sigma), pH 4.1, for 20 min at RT. For immunocytochemistry, cultures were blocked and permeabilized in 5% normal donkey serum, 1% bovine serum albumin and 0.3% Triton X-100 (all from Sigma) in PBS. Incubation with the primary antibody against GFP (1:500; Sigma) was performed in PBS with 3% normal donkey serum at 4 1C overnight. For visualization of the staining, a secondary Alexa 488-conjugated donkey anti-mouse antibody (1:800; Invitrogen) was added for 1 h at RT. Omission of the primary antibody served as negative control.
To initiate differentiation into cartilage, 200 000 cells were centrifuged at 450 g. The pellets were cultured for 21 days under serum-free conditions in 500 ml high-glucose Dulbecco's modified Eagle's medium (Invitrogen), 10 ng ml -1 transforming growth factor-b3 and 500 ng ml -1 bone morphogenetic protein-6 (R&D Systems, Minneapolis, MN, USA), 100 nM dexamethasone, 50 mg ml -1 L-ascorbate-2-phosphate, 40 mg ml -1 L-proline (Sigma), 100 mg ml -1 pyruvate (Sigma) and 50 mg ml -1 ITS+Premix (Becton Dickinson, Heidelberg, Germany). The pellets were fixed with 4% paraformaldehyde, embedded into paraffin and cut into 5 mm thick sections on a microtome. Chondrogenic differentiation was visualized by Toluidine blue staining (Sigma).
Proliferation assays
Proliferative capacity of mMSCs was assessed by growth curves. Passage 8 cells were seeded at 50 cells cm -2 into 58 cm 2 Petri dishes. Three plates were trypsinized each day for the duration of 10 days. After Trypan blue staining, numbers of viable cells were counted in a Fuchs-Rosenthal chamber.
FACS analysis
Flow cytometry was performed with Cytomics FC 500 FACS (Beckman Coulter, Miami, FL, USA) and FACSCalibur (Becton Dickinson). A total of 300 000 cells from passage 8 were centrifuged at 500 g for 5 min, resuspended in 1 ml PBS and stained for 20 min at RT on a shaker. The cells were incubated with the following antibodies from Becton Dickinson: CD3e-FITC, CD11b-PE, CD29-FITC, CD34-PE, CD40-APC, CD45-PE, CD45R/B220-FITC, CD80-PE, CD86-APC, MHCII-PE, Sca1-PE (Ly6A/E), VCAM1-FITC (CD106), CD90.1-PE (Thy1.1), CD90.2-FITC (Thy1.2), CD117-FITC (c-kit), Flk1-PE (VEGF-R2), CD31-FITC (PECAM-1), Ly6G/Ly6C-FITC, Ter119/Erythroid cells-PE, and with CD44-FITC antibody (generously provided by DRFZ, Berlin, Germany).
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The following isotype controls were used: PE-conjugated rat IgG2ak, PEconjugated hamster IgG2k, PE-conjugated mouse IgG2ak, FITC-conjugated rat IgG2b and APC-conjugated rat IgG2ak. Before FACS analysis, cells were centrifuged and washed twice with PBS. Analysis of the FACS data was carried out with WinMDI software or CellQuest Pro software (Becton Dickinson).
Plasmids
Either the 4.7 kb pEGFP-N2 control vector (Clontech, Saint-Germain-en-Laye, France) or the 6.0 kb pEPO-IRES2-EGFP vector was used for experiments. To generate pEPO-IRES2-EGFP vector, the complementary DNA (cDNA) encoding for murine epo was amplified by PCR from total RNA isolated from kidneys of C57BL/6 mice by TRIzol RNA extraction (Invitrogen). Purified RNA was reverse transcribed into single-strand cDNA using Moloney murine leukemia virus reverse transcriptase (Promega, Mannheim, Germany). Nucleofection. Before transfection, cells were grown for 7 div, trypsinized and centrifuged at 200 g. 1Â10 6 cells were resuspended in 100 ml nucleofection buffer (Nucleofector Kit for rat neurons, Lonza) and nucleofected with 5 mg DNA using program A-30 of the Amaxa nucleofector device (Lonza). After nucleofection, 500 ml CM was added to the nucleofection cuvette (Peqlab Biotechnology GmbH, Erlangen, Germany), and the cells were carefully transferred into a 58 cm 2 dish. Cell debris was removed by a medium change at 3 h post transfection, followed by addition of 10 ml fresh CM.
Transient transfection of mMSCs
Lipofection. mMSCs were seeded at 50 cells cm -2 into a 12-well plate and were allowed to grow for 7 div. Cells were transfected in OptiMEM with Lipofectamin 2000 (Invitrogen) according to the manufacturer's instructions. As a modification to the protocol, 4 mg DNA was combined with 4 ml Lipofectamin in 200 ml OptiMEM. Cells were rinsed twice with OptiMEM, and 1 ml of OptiMEM plus DNA/Lipofectamin complexes were added to each well. After 3.5 h, cells were rinsed once with CM followed by complete medium change.
Magnetofection. Cells were plated at 50 cells cm -2 in a 96-well dish and were incubated for 7 div. DNA was mixed with CombiMAG nanoparticles (Chemicell, Berlin, Germany) for 15 min at RT in a volume of 80 ml OptiMEM. Lipofectamin was diluted in a volume of 80 ml OptiMEM and then transferred to the DNA/nanoparticle mixture, followed by incubation for another 20 min at RT. Wells were rinsed twice with OptiMEM to remove interfering serum particles and 110 ml of fresh OptiMEM was added to each well. Then, 10 ml of DNA/CombiMAG/Lipofectamin complexes were added to each well (15 wells per plasmid). Each single well was transfected with 150 ng DNA (1 mg ml -1 ) combined with CombiMAG nanoparticles in a ratio of 1:1 (vol:vol) and 0.2 ml Lipofectamin. Magnetic field was applied immediately on the MagnetoFAC-TOR-96 plate (Chemicell) for 5 min at RT. After transfection, a complete medium change was performed.
Transfection rates for nucleofection, lipofection and magnetofection were determined at 48 h after transfection by FACS analysis (percentage GFP expression).
Stable transfection of mMSCs
mMSCs were transiently transfected with pEGFP-N2 control vector or pEPO-IRES2-EGFP vector, and stable transfectants were selected by addition of CM supplemented with 400 mg ml -1 G418-disulfate (Geneticin, Invitrogen) for 14 div. Thereafter, cells were trypsinized and single GFP-expressing cells were sorted by FACS (Moflo, DakoCytomation, Hamburg, Germany) into each well of a 96-well plate. By using this sc-CFU assay, the sorted cells gave rise to one or more single cell-derived colonies in each well. Plates were screened for colonies with high GFP expression by fluorescence microscopy. GFP-positive, single cellderived clones were expanded in 145 cm 2 dishes. After passages 10 to 11, single cell-derived clones were analyzed for GFP expression by FACS.
PCR analyses
To confirm the presence of the transgenes, DNA was extracted from stably transfected mMSCs by DNeasy Blood & Tissue Kit (Qiagen). Resulting DNA was subjected to RNase treatment and for PCR analysis the following primers were used: CMV forward, 5¢-CGTAACAACTCCGCCCCATT-3¢; EGFP reverse, 5¢-GGCCGTTTACGTCGCCGT-3¢; IRES reverse, 5¢-GACGGCAATATGGTGG AAA-3¢; b-actin forward, 5¢-ACCCACACTGTGCCCATCTA-3¢; b-actin reverse, 5¢-GCCACAGGATTCCATACCCA-3¢. PCR was run with 100 ng genomic DNA using AmpliTaq DNA polymerase (Applied Biosystems, Darmstadt, Germany) in a PCR machine (Eppendorf Mastercycler Gradient, Wesseling-Berzdorf, Germany). 
Enzyme-linked immunosorbent assays
The amount of EPO in supernatants of EPO-expressing mMSCs or in serum samples from transplanted mice was determined using the Quantikine mouse/ rat immunoassay ELISA kit (R&D Systems, Wiesbaden, Germany) according to the manufacturer's instructions. For the anti-EPO antibody ELISA, Maxisorb 96-well plates (Nunc, Thermo Scientific, Langenselbold, Germany) were coated with 0.5 mg ml -1 recombinant murine EPO (R&D Systems) in coating buffer overnight at 4 1C. After washing three times, wells were blocked with ELISA Diluent solution (eBioscience, NatuTec, Frankfurt am Main, Germany) for 1 h at RT. After further washing, murine serum was applied in 1:100 dilutions to the wells. For establishment of a standard curve, 50 ml per well of a rabbit polyclonal antibody against EPO (H-162) (Santa Cruz, Heidelberg, Germany) was added to some additional wells in varying concentrations. After 2 h of incubation, the wells were washed five times. For detection of bound anti-EPO antibodies, a 1:10 000 dilution of a 1 mg ml -1 horseradish peroxidase (HRP)-conjugated rabbit-anti-mouse antibody was used for serum samples and a 1:10 000 dilution of a 1 mg ml -1 goat-anti-rabbit HRP-coupled antibody (both from Bethyl Laboratories, Montgomery, TX, USA) was used for anti-EPO antibody detection in wells of the standard curve. After a 1-h incubation and further washing, ABTS substrate (Invitrogen) was added and color development was finished by addition of stop solution (0.1 M citric acid). The assay was measured by an ELISA-Reader at 405 nm. Values are expressed as anti-EPO equivalents, because a commercial mouse anti-mouse antibody is not available for precise quantification.
For anti-GFP antibody ELISA, the same protocol as for the anti-EPO antibody ELISA was used with the following modifications: Maxisorb 96-well plates were coated with 1 mg ml -1 recombinant EGFP (Biovision Inc., Mountain View, CA, USA). After blocking and washing steps, murine serum samples were applied in 1:10 dilutions to the wells. For the standard curve, 50 ml per well of a mouse-anti-GFP antibody (Sigma) was added to additional wells in varying concentrations. For the detection of bound anti-GFP antibodies, a 1:10 000 dilution of a 1 mg ml -1 HRP-conjugated rabbit-anti-mouse antibody (Bethyl Laboratories) was used for serum and standard curve samples.
EPO immunoprecipitation and western blot
Supernatants from mMSC cultures (1 ml) were used for immunoprecipitation of recombinant EPO. Samples from EPO-expressing mMSCs contained a concentration of 40.1 ng ml -1 EPO as measured by ELISA.
Before use, protein G agarose beads (Sigma) were washed in PBS three times. Cell culture supernatants were incubated with beads at 4 1C on a rotating device for 1 h. Beads were removed from the samples, and 5 mg or 10mg of EPO antibody (Santa Cruz) were incubated with the samples at 4 1C on a rotating device overnight. On the next day, 30 ml of washed beads were added to each sample and incubated at 4 1C on a rotating device for 1.5 h. Samples were centrifuged and the beads were washed three times with 1 ml PBS. Beads were resuspended in 50 ml sample buffer and boiled. A total of 40 ml of each sample and 5 ng of recombinant murine EPO were loaded onto a denaturing 4-20% Tris-HEPES gel (Pierce, Thermo Fisher Scientific, Bonn, Germany). Western blotting and antibody incubation were performed after polyacrylamide gel electrophoresis using a primary antibody against EPO (1:1000; Santa Cruz) and a secondary HRP-conjugated secondary anti-rabbit antibody (GE Healthcare, Munich, Germany). Chemiluminescence detection was performed using a cooled CCD camera (Finger Lakes Instrumentation, Lima, NY, USA, PL09000). Image processing was performed in ImageJ (McMaster Biophotonics ImageJ distribution, McMaster University, Hamilton, ON, Canada, www.macbiophotonics.ca). For figure preparation, 16bit TIF images were converted to 8bit TIF, the image was cropped and brightness and contrast adjusted uniformly.
Mouse CFU-E assay
The biological activity of EPO produced by mMSC was assessed by CFU-E assay. In brief, 200 000 BM cells from C57BL/6 mice were plated in six-well plates with cytokine-free Methocult medium (Stem Cell Technologies, Cell Systems, St Katharinen, Germany). To stimulate CFU-E formation, supernatant from mMSCs transfected with pEPO-IRES2-EGFP vector was assessed for EPO concentration by ELISA (R&D Systems), and an amount of mMSC supernatant containing 15 ng ml -1 EPO was added to the BM cells. Control medium without EPO served as negative control. As a positive control, commercially available recombinant human EPO (1.5 U ml -1 ; Roche, Mannheim, Germany) was added to the BM cells. Each experiment was performed in duplicate. At 48 h after plating, clusters of erythroid progenitors were counted in each well using light microscopy (Olympus CKX41, Hamburg, Germany).
Intraperitoneal transplantation of gene-modified mMSCs
All animal experiments were performed in accordance with the standards for animal care of our institution. Permission was obtained from the LAGeSo according to the national regulations. To investigate in vivo effects of stably transfected mMSCs, we injected either mMSCs stably transfected with pEPO-IRES2-EGFP, mMSCs stably transfected with the control pEGFP-N2 vector or PBS i.p. into male C57BL/6 mice aged 8-12 weeks. On day 0, 2Â10 7 cells of each mMSC clone or PBS alone were injected, and 1Â10 7 cells of each mMSC clone or PBS alone were injected on days 2 and 3, respectively, in a volume of 1 ml PBS. At 7 and 35 days after the first injection, peripheral blood samples were collected by retro-orbital bleeding. The samples were analyzed for hematocrit by standard micro-hematocrit procedure in duplicate, for hemoglobin by QuantiChrom hemoglobin assay (Bioassay systems, Cologne, Germany), for EPO serum levels by Quantikine mouse/rat immunoassay ELISA kit (R&D Systems) and for anti-EPO antibody synthesis.
Statistical analysis
Results are expressed as means ± s.d. For statistical analysis, a paired t-test, oneway analysis of variance with Bonferroni's post hoc test or two-way analysis of variance with post hoc test were used. The P-values of o0.05 were considered statistically significant.
